Creative Medical Technology Holdings Announces Mid-Term Follow-up Study Data Reporting Significant Reduction in Opioid Use by Chronic Lower Back Pain Patients Undergoing StemSpine® Procedure using AlloStem™
Portfolio Pulse from
Creative Medical Technology Holdings reported positive mid-term follow-up data from its StemSpine® pilot study, showing significant reduction in opioid use and improvements in pain and mobility for chronic lower back pain patients using AlloStem™ cells.
February 14, 2025 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Creative Medical Technology Holdings announced positive mid-term data from its StemSpine® study, showing reduced opioid use and improved mobility in patients, which could boost investor confidence and stock price.
The announcement of significant reductions in opioid use and improvements in patient outcomes from the StemSpine® study is likely to enhance investor confidence in Creative Medical Technology Holdings. This positive development in their regenerative medicine solutions could lead to an increase in stock price as it demonstrates the effectiveness of their products and potential market impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100